ORCA
Online Research @ CardiffÂ
Browse by Current Cardiff authors
![[up]](/style/images/multi_up.png)
Up a levelNumber of items: 5.
Carucci, Margherita, Clamp, Andrew, Zhou, Cong, Hurt, Chris, Glasspool, Rosalind, Monaghan, Phillip J., Thirkettle, Sally, Wheatley, Michael, Mahmood, Madia, Narasimham, Monica, Cox, Tracy, Morrison, Hilary, Campbell, Susan, Nelson, Annmarie, Holland-Hart, Daniella  ORCID: https://orcid.org/0000-0002-1127-5152, Hopewell-Kelly, Noreen, Thomas, Abin, Porter, Catharine, Slusarczyk, Magdalena ORCID: https://orcid.org/0000-0002-4707-7190, Irving, Alys, Dive, Caroline, Adams, Richard and Jayson, Gordon C.
2024.
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors.
BMC Cancer
24
(1)
, 1309.
10.1186/s12885-024-13073-0
|
|
|
Beresford, Mark, Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Hudson, Zoe, Carucci, Margherita, Ingarfield, Kate, Gee, Julia ORCID: https://orcid.org/0000-0001-6483-2015, Smith, Joanna ORCID: https://orcid.org/0000-0003-4234-6686, Kitson, Terri ORCID: https://orcid.org/0000-0001-6333-046X, Alchami, Fouad, Madden, Tracie-Ann ORCID: https://orcid.org/0000-0001-7880-7873, Hayward, Larrie, Hwang, David, Spensley, Saiqa, Waters, Simon, Wheatley, Duncan and Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496
2023.
Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial.
BJC Reports
1
(1)
, 13.
10.1038/s44276-023-00016-8
|
|
|
|
Jayson, G., Carucci, Margherita, Hurt, Christopher ORCID: https://orcid.org/0000-0003-1206-8355, Zhou, Cong, Monaghan, Phillip, Wych, Julie, Irving, Alys, Narasimham, Monica, Morrison, Hilary, Campbell, Sue, Glasspool, Rosalind, Longo, Mirella ORCID: https://orcid.org/0000-0002-9867-3806, Nelson, Annmarie ORCID: https://orcid.org/0000-0002-6075-8425, Dive, Caroline, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243 and Clamp, Andrew
2021.
VALTIVE1: Validation of Tie2 as a response biomarker for VEGF inhibitors In Ovarian Cancer.
Presented at: NCRI Cancer Conference,
2021.
|
|
|
Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496, Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Carucci, Margherita, Cox, Catrin, Butler, Rachel, Alchami, Fouad, Madden, Tracie-Ann ORCID: https://orcid.org/0000-0001-7880-7873, Bale, Catherine, Bezecny, Pavel, Joffe, Johnathan, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, Foxley, Andrew and Howell, Sacha J.
2020.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncology
21
(3)
, pp. 345-347.
10.1016/S1470-2045(19)30817-4
|
|
|
|
Hurt, Christopher N. ORCID: https://orcid.org/0000-0003-1206-8355, Jones, Sadie E. F., Madden, Tracie-Ann ORCID: https://orcid.org/0000-0001-7880-7873, Fiander, Alison, Nordin, Andrew J., Naik, Raj, Powell, Ned, Carucci, Margherita and Tristram, Amanda
2018.
Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multi-centre, randomised, phase II trial (RT3VIN).
BJOG: An International Journal of Obstetrics and Gynaecology
125
(9)
, pp. 1171-1177.
10.1111/1471-0528.15124
|
|
|